Ng P C, Wong G W, Lam C W, Lee C H, Fok T F, Wong M Y, Ma K C
Department of Paediatrics Prince of Wales Hospital Chinese University of Hong Kong.
Arch Dis Child Fetal Neonatal Ed. 1999 May;80(3):F213-6. doi: 10.1136/fn.80.3.f213.
To evaluate the pituitary-adrenal function of preterm infants whose mothers received multiple courses (8 or more doses) of antenatal dexamethasone.
The pituitary-adrenal function of 14 preterm infants whose mothers received eight or more doses of antenatal dexamethasone were assessed using the human corticotrophin releasing hormone (hCRH) stimulation test when 7 days (n = 14) and 14 days old (n = 12). During each test, blood samples were taken at 0 (baseline), 15, 30 and 60 minutes after an intravenous bolus dose of hCRH (1 microg/kg). The corresponding hormone concentrations were compared between days 7 and 14, and with various associated factors.
The baseline (0 min) plasma adrenocorticotrophic hormone concentration was significantly higher at day 14 than at day 7 (p = 0.036). None of the corresponding poststimulation (15, 30, and 60 min) hormone concentrations was significantly different between the two time epochs. When the association between the hormone concentrations and the number of antenatal dexamethasone doses received by the mothers was assessed, a significant negative correlation was observed in serum cortisol concentrations at 15 and 30 min on day 14 (r = -0.59, p = 0.04 and r = -0.60, p = 0.039, respectively).
The absence of a significant difference in poststimulation hormone concentrations between days 7 and 14 in this cohort of infants, and the similarity of their hormone responses with those of older children and adults, suggests that no severe pituitary-adrenal suppression had occurred. None the less there was evidence of mild adrenal suppression in some of the treated infants. Vigilance in monitoring blood pressure, electrolytes and signs of adrenal suppression in infants whose mothers receive multiple courses (8 or more doses) of antenatal dexamethasone is required, as some of them might have diminished adrenal reserve.
评估母亲接受多疗程(8剂或更多剂)产前地塞米松治疗的早产儿的垂体-肾上腺功能。
对14名母亲接受8剂或更多剂产前地塞米松治疗的早产儿,在其7日龄(n = 14)和14日龄(n = 12)时使用人促肾上腺皮质激素释放激素(hCRH)刺激试验评估垂体-肾上腺功能。在每次试验中,静脉推注hCRH(1微克/千克)后,于0(基线)、15、30和60分钟采集血样。比较7日龄和14日龄时相应激素浓度,并与各种相关因素进行比较。
14日龄时的基线(0分钟)血浆促肾上腺皮质激素浓度显著高于7日龄(p = 0.036)。两个时间段相应的刺激后(15、30和60分钟)激素浓度均无显著差异。在评估激素浓度与母亲产前接受地塞米松剂量数之间的关联时,观察到14日龄时15分钟和30分钟血清皮质醇浓度存在显著负相关(分别为r = -0.59,p = 0.04和r = -0.60,p = 0.039)。
该队列婴儿在7日龄和14日龄时刺激后激素浓度无显著差异,且其激素反应与大龄儿童和成人相似,表明未发生严重的垂体-肾上腺抑制。尽管如此,一些接受治疗的婴儿仍有轻度肾上腺抑制的证据。对于母亲接受多疗程(8剂或更多剂)产前地塞米松治疗的婴儿,需要警惕监测血压、电解质和肾上腺抑制体征,因为其中一些婴儿可能肾上腺储备减少。